• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

  • — 15 Dec, 2007
AudioMedica News
AudioMedica News
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
00:00 /
RSS Feed
Share
Link
Embed
Jack Cuzick
Jack Cuzick

JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071214_jack_cuzick.mp3]

You may also like...

  • Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia 24 Jan, 2014
  • ASCO Annual Meeting Daily News Podcasts – June 4th, 2007 ASCO Annual Meeting Daily News Podcasts – June 4th, 2007 5 Jun, 2007
  • The Disappointment of the NSABP C-08 Trial The Disappointment of the NSABP C-08 Trial 16 Sep, 2009
  • Previous story New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
  • Next story Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Which Tasks Most Influence Pediatric PT Productivity,…
    • New Front Line Standard for Older Patients with Chronic…
  • Home
  • Oncology
  • ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.